OGXI 2.09 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:39 AM

OGXI 2.09 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week low of 2.08 Closing the day 10:42 at 2.09 -0.01 -0.48% With a day low of 2.08 and a total volume of 35,341.

OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/

OGXI Oncogenex Pharmaceuticals Inc Recent Headline News

OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.07 (-0.03)

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 302.05 (-1.56), ALNY: 89.21 (-0.36), ISIS: 51.59 (+1.53), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05), RGLS: 15.59 (-0.67), GSK: 46.43 (+0.18), SNY: 46.98 (-1.11)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.30 (+0.02), PCYC: 138.53 (-0.07), CLDX: 20.94 (+2.21), INCY: 71.85 (+0.55), BIND: 7.78 (-0.62), CELG: 107.77 (+0.79), OMER: 21.48 (+0.51), VSTM: 8.74 (-0.07), GILD: 102.72 (+0.38), OGXI: 2.07 (-0.03), ANTH: 1.84 (-0.01), NVAX: 5.01 (+0.17)

OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST

OGXI: 2.07 (-0.03)

More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT

OGXI: 2.07 (-0.03)

OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OGXI: 2.07 (-0.03)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE

RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...
OGXI: 2.07 (-0.03), MCGC: 3.69 (unch), INVN: 15.42 (+0.28), DRL: 5.35 (+0.09), ARCP: 9.09 (+0.32)

OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT

OGXI: 2.07 (-0.03)

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.07 (-0.03)

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 47.02 (+0.18), ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.78 (-0.02), ANY: 8.00 (-0.39), OGXI: 2.07 (-0.03), GLYC: 8.19 (+0.41)

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.07 (-0.03), ARTX: 2.30 (+0.06), CYTR: 2.57 (-0.06), CNCE: 12.74 (-0.07)

OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), UTHR: 128.79 (+0.79), TEVA: 57.30 (+0.05)

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)

Achieve Life Sciences (ACHV) Stock Research Links

ACHV Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Qapture Expands Global DeFi Reach with Key Acquisitions

Qapture Investments just made a move in the digital finance space that's promising to turn some heads. From acquiring Flammarion Partners to snapping up Hermetik Trading's DeFi strategies, this Bermuda-based investment manager isn't here to play. Led by Frederick Pye, the firm's gearing up for an industry takeover by blending regulation with innovative digital finance...

TVEyes Archive+: Revolutionizing Media Intelligence

TVEyes Archive+ Takes Media Intelligence to New Heights Dishing out another update here, folks. TVEyes, the media intelligence powerhouse, just kicked off something that's got the potential to change the strategic media game—they call it Archive+. This tool isn’t just plundering old tapes; we're talking nearly two damn decades worth of historical broadcasts and...

Plan A Bets on AI in High-Stakes M&A Arena

Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...

Vanda Pharmaceuticals Steps Into September Investor Talks

Vanda Pharmaceuticals Heads Into Key Investor Spotlights In the relentless quest for market edge, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is setting the stage for what could be some telling moments in September 2026. Investors with a keen interest in the pharmaceutical realm should seat themselves upfront as Vanda takes the floor in a series of pivotal conferences. Each...

Jamba's Cloud Whip: A Bold Blend in Beverage Scene

An Unexpected Shake-Up in the Beverage Game Folks, brace yourselves because Jamba's making some bold moves. I remember a time when a smoothie was just a smoothie, but now, they're stacking up a new deck with this fancy thing they're calling 'Cloud Whip'. It's basically a way to slap some extra protein onto your drink, with 10 grams coming at you like a freight train...

Equinix and CPP Investments Finalize $4B Data Center Deal

Equinix's Nordic Expansion: A Bold Move Ever seen a chess master make a move that completely shifts the board? That's what Equinix, Inc. and CPP Investments just pulled off with their acquisition of atNorth. With a hefty price tag of $4 billion, they're not just playing around. This deal puts Equinix at the center of the Nordic data hub, solidifying its foothold in a...

Codoxo Snags 2026 Award for AI Payment Innovation

Revolutionizing Healthcare Payment with AI Ah, healthcare and payments—two things that can make even the most patient folks lose their cool. But here comes Codoxo, shaking up this landscape with its Point Zero Payment Integrity solution, and someone's finally giving them the nod they deserve. For those of us who have been in the game for a while, this announcement is...

ECARX Leverages AI for Next-Gen Auto Intelligence

ECARX's Latest Ventures in AI-Driven Mobility ECARX is making waves with its recent announcement to integrate Tencent Cloud's WorkBuddy AI with the Flyme AIOS operating system. It's not a small tweak; it's a big leap forward in pushing AI boundaries in automobiles. If you're looking at ECARX Holdings Inc. (Nasdaq: ECX) as an investment, here's the meat and potatoes of...

STANLEY Dives Into Flooring: Strategic Move or Risky Bet?

STANLEY® Floors: The New Frontier? Who would've thought STANLEY®, the tool giant founded back in 1843, would dive headfirst into the flooring market? This isn’t just any leap; it's a strategic handshake with Area Floors, and they’re dragging along i4F’s renowned drop-lock tech for good measure. What does this mean for the flooring landscape and STANLEY's brand...

California's Insurance Shake-up: What It Means

There are plenty of rules in life that seem useless until suddenly they're not. California just passed a few fresh ones aiming to rein in the insurance sector. Zap your attention over to three new bills targeting fair insurance payouts and boosting coverage availability. It's a gust of wind in a typically frustrating insurance landscape, especially for the folks who've...